摘要
目的:探讨miR-19a与中晚期宫颈癌同步放化疗敏感性的相关性及可能作用机制。方法:收集行同步放化疗治疗的ⅡB～ⅢB期宫颈鳞状细胞癌患者20例,根据其治疗后6个月的近期治疗效果分为治疗敏感组和抗拒组,每组各10例,治疗前收集宫颈肿瘤组织并提取总RNA;利用TaqMan Real-time PCR法检测miR-19a在两组间的表达情况,统计分析其与同步放化疗敏感性的相关性。结果:敏感组随访10～20个月,截止末次随访均未发现肿瘤复发。抗拒组治疗中肿瘤进展2例,治疗结束6个月内肿瘤残存或出现新发病灶者8例。两组患者在临床分期、年龄、组织分级、淋巴结转移、局部肿瘤大小、Scc-Ag水平和治疗时间各个临床因素差异无统计学意义,P值均>0.05;miR-19a在治疗抗拒组中的表达水平约为1.0±0,敏感组为4.80±1.15,两组比较差异有统计学意义,P<0.05。结论:miR-19a与中晚期宫颈癌同步放化疗敏感性相关,可能成为预测宫颈肿瘤内在放化疗敏感性的标志,对尽早施行个体化治疗以改善预后有重要意义。
OBJECTIVE： To investigate miR-19a that related to the concomitant chemoradiotherapy sensitivity in adr vanced uterine cervical squamous cell carcinomasuterine （UCSCC）,and find a marker to identify cervical cancer patients who are resistant to the concomitant chemoradiotherapy. METHODS： The UCSCC patients in FIGO stage Ⅱ B or Ⅲ B were treated with platinum based concomitant chemoradiotherapy. Patients with progressive disease during first line platinum hased chemotherapy or those who suffered recurrent disease within 6 months of completing first line therapy were termed resistant. Patient with no recurrence or with recurrences beyond 6 months were termed sensitive. All tumor tissues biopsies were collected before treatment with standard chemoradiation. Total RNAs were isolated using a mirVana RNA isolation kit （Ambion） according to the manufacturer＇s protocol. The expression level of miR-19a was examined by using TaqMan Real-time PCR in 20 cervix biopsies samples,including 10 resistant samples and 10 sensitive samples. RESULTS： The follow-up time of sensitive samples was 10--20 months,and no recurrence patient was found. In resistance samples, there were 2 cases with cancer processing, and 8 cases with new lesions. There were no difference of clinical staging,age, histology degree,lymph node metastasis, tumor size, Scc-Ag level and treatment time between sensitive samples and resistant samples （P〉0.05）. The expression of miR-19a in resistance samples was 1.0±0,and 4.80±1.15 in sensitive samples （P〉0.05）. CONCLUSIONS： miR-19a may be a marker to identify cervical cancer patients who are likely to fail concomitant chemoradiotherapy,in order to apply individualized therapy. It is worthy to verify role of miR-19a in cervical cancer cells and worthy of further investigation.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2013年第8期604-606,共3页
Chinese Journal of Cancer Prevention and Treatment
基金
中央级公益性科研院所基本科研业务费(JK2009B07)
